Disclosure Of Entity's Operating Segments [Text Block]

Egetis Therapeutics - Filing #678413

Concept As at
2023-12-31
2023-01-01 to
2023-12-31
2022-01-01 to
2022-12-31
As at
2022-12-31
Disclosure of entity's operating segments [text block]
NOT
Disclosure of operating segments [text block]
Disclosure of operating segments [abstract]
Disclosure of operating segments [line items]
Revenue
576,000,000 SEK
226,000,000 SEK
Tax expense (income)
1,000,000 SEK
- SEK
Profit (loss) before tax
3,268,000,000 SEK
1,938,000,000 SEK
Profit (loss)
3,269,000,000 SEK
1,938,000,000 SEK
Assets
7,602,000,000 SEK
5,611,000,000 SEK
Cash flows from (used in) operating activities
2,784,000,000 SEK
1,735,000,000 SEK
Cash flows from (used in) investing activities
0 SEK
17,000,000 SEK
Cash flows from (used in) financing activities
4,589,000,000 SEK
1,557,000,000 SEK
Disclosure of products and services [text block]
Disclosure of products and services [abstract]
Disclosure of products and services [line items]
Disclosure of geographical areas [text block]
Disclosure of geographical areas [abstract]
Disclosure of geographical areas [line items]
Disclosure of major customers [text block]
Disclosure of major customers [abstract]
Disclosure of major customers [line items]

Talk to a Data Expert

Have a question? We'll get back to you promptly.